Astra and Daiichi beat Gilead to the punch, at least in one setting.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
Efficacy looks better with daraxonrasib plus chemo versus monotherapy, but toxicity looms.
Pivotal data set the stage for slightly delayed US accelerated approval filing.
But first it will need to identify the optimal dose in first-line small-cell lung cancer.
Inlexzo gets the nod in BCG-unresponsive non-muscle invasive bladder cancer, but the group has bigger plans.
So far the data, with a Car-T Legend licensed to Novartis, lag antibody approaches.
The latest projects newly into human trials include BNT3212.